Detalhe da pesquisa
1.
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
N Engl J Med
; 385(4): 320-329, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192428
2.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
N Engl J Med
; 385(15): 1355-1371, 2021 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496194
3.
Vaccine Effectiveness Against SARS-CoV-2 Related Hospitalizations in People who had Experienced Homelessness or Incarceration - Findings from the Minnesota EHR Consortium.
J Community Health
; 49(3): 448-457, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066221
4.
Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status.
J Infect Dis
; 2023 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950884
5.
Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network.
J Infect Dis
; 228(2): 185-195, 2023 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683410
6.
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.
J Infect Dis
; 227(8): 961-969, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36415904
7.
Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
J Infect Dis
; 227(12): 1348-1363, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806690
8.
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.
Clin Infect Dis
; 76(3): e1168-e1176, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031405
9.
Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses.
Clin Infect Dis
; 76(10): 1822-1831, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36578137
10.
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers.
Emerg Infect Dis
; 29(3): 599-604, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36703252
11.
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
Clin Infect Dis
; 75(1): e827-e837, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928334
12.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(4): 139-145, 2022 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35085224
13.
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
MMWR Morb Mortal Wkly Rep
; 71(13): 495-502, 2022 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358170
14.
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
MMWR Morb Mortal Wkly Rep
; 71(11): 422-428, 2022 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298453
15.
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(7): 255-263, 2022 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35176007
16.
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(9): 352-358, 2022 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35239634
17.
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep
; 71(29): 931-939, 2022 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862287
18.
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.
JAMA
; 328(15): 1523-1533, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36255426
19.
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.
Clin Infect Dis
; 73(11): 1973-1981, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245243
20.
Performance of Symptom-Based Case Definitions to Identify Influenza Virus Infection Among Pregnant Women in Middle-Income Countries: Findings From the Pregnancy and Influenza Multinational Epidemiologic (PRIME) Study.
Clin Infect Dis
; 73(11): e4321-e4328, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33173947